Barclays analyst Luke Sergott upgrades Icon (NASDAQ:ICLR) from Equal-Weight to Overweight.
Barclays Upgrades Icon to Overweight
Barclays analyst Luke Sergott upgrades Icon (NASDAQ:ICLR) from Equal-Weight to Overweight.
Related Posts
Sermonix Pharmaceuticals’ Lasofoxifene, Will Be Evaluated In A New Study Arm Of The Ongoing I-SPY Endocrine Program Sponsored By Quantum Leap Healthcare Collaborative, In Newly Diagnosed ER+ Invasive Cancer, Lasofoxifene Was In-Licensed From Ligand Pha…
The arm is part of the I-SPY 2 Endocrine Optimization Platform (EOP), which is focused on patients with clinically high-risk (stage 2/3) estrogen receptor-positive (ER+)/HER2- breast cancer, but the molecularly
AstraZeneca Announced Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.
Vertex To Present New Data Demonstrating Significant Benefits Of Treatment With TRIKAFTA At The ECFS 47th European Cystic Fibrosis Conference Held June 5-8, 2024
- Results from a randomized, placebo-controlled study of TRIKAFTA® in people with cystic fibrosis with rare, non-F508del CFTR mutations showed statistically significant and clinically meaningful improvements in the